Back to User profile » Dr Luca Potestio
Papers published by Dr Luca Potestio:
IL-23 Inhibitors in Psoriasis: What Have We Learnt so Far?
Megna M, D’Agostino M, Feo F, Ventura V, Tommasino N, Potestio L
Journal of Inflammation Research 2026, 19:540848
Published Date: 10 February 2026
Efficacy and Safety of Hormonal Therapies for Acne: A Narrative Review
Tommasino N, Annunziata MC, Potestio L, Napolitano M
Clinical, Cosmetic and Investigational Dermatology 2025, 18:3331-3337
Published Date: 6 December 2025
Guselkumab In A Subset Of Multifailure Patients With Hidradenitis Suppurativa: Real-Word Evidence from Federico II
Martora F, Tommasino N, Coronella L, Potestio L, Battista T, Megna M
Clinical, Cosmetic and Investigational Dermatology 2025, 18:2387-2393
Published Date: 19 September 2025
Long-Term Real-World Effectiveness and Drug Survival of Guselkumab in Patients with Psoriasis: A 5-Year Retrospective Study
Mortato E, Talamonti M, Marcelli L, Megna M, Raimondo A, Caldarola G, Bernardini N, Balato A, Campanati A, Esposito M, Bonifati C, Lora V, Potestio L, Lembo S, Loconsole F, De Luca E, Skroza N, Buononato D, Bianchelli T, Fargnoli MC, Tommasino N, Foti C, De Simone C, Bianchi L, Galluzzo M
Psoriasis: Targets and Therapy 2025, 15:455-469
Published Date: 16 September 2025
Hidradenitis Suppurativa Cancer Risk: A Review of the Literature
Martora F, Tommasino N, Battista T, Potestio L, Megna M
Clinical, Cosmetic and Investigational Dermatology 2025, 18:617-626
Published Date: 18 March 2025
Effectiveness and Safety of Dupilumab and Tralokinumab for Treating Atopic Dermatitis and Pruritic Skin Disorders in Oncological Patients: A Narrative Review
Lauletta G, Potestio L, Patruno C, De Lucia M, Napolitano M
Clinical, Cosmetic and Investigational Dermatology 2025, 18:311-317
Published Date: 30 January 2025
Hypergammaglobulinemia in Hidradenitis Suppurativa Patients: A New Emerging Association
Martora F, Battista T, Giordano A, Potestio L, Megna M
Clinical, Cosmetic and Investigational Dermatology 2025, 18:1-5
Published Date: 7 January 2025
Tralokinumab for the Treatment of Adult Atopic Dermatitis in Special Populations
Potestio L, Patruno C, Dastoli S, Brescia C, Napolitano M
Journal of Asthma and Allergy 2024, 17:791-799
Published Date: 14 August 2024
A Case of Erythrodermic Psoriasis Successfully Treated with Risankizumab [Corrigendum]
Megna M, Ruggiero A, Salsano A, Lauletta G, Portarapillo A, Torta G, Martora F, Potestio L
Clinical, Cosmetic and Investigational Dermatology 2024, 17:1447-1448
Published Date: 18 June 2024
Risk Factors for Psoriasis Flares: A Narrative Review
Potestio L, Lauletta G, Tommasino N, Portarapillo A, Salsano A, Battista T, Martora F, Megna M
Psoriasis: Targets and Therapy 2024, 14:39-50
Published Date: 30 May 2024
Secukinumab for Severe Hidradenitis Suppurativa in a Patient on Haemodialysis: Efficacy and Safety on 300 mg Every 2 Weeks Administration – A Case Report
Martora F, Annunziata MC, Potestio L, Battista T, Ruggiero A, Megna M
Clinical, Cosmetic and Investigational Dermatology 2024, 17:1275-1279
Published Date: 30 May 2024
Effectiveness and Safety of Tildrakizumab in Psoriasis Patients Who Failed Anti-IL17 Treatment: A 28-Week Real-Life Study
Megna M, Ruggiero A, Tommasino N, Brescia C, Martora F, Cacciapuoti S, Potestio L
Clinical, Cosmetic and Investigational Dermatology 2024, 17:1037-1042
Published Date: 7 May 2024
The Role of Interleukin 23/17 Axis in Psoriasis Management: A Comprehensive Review of Clinical Trials
Potestio L, Martora F, Lauletta G, Vallone Y, Battista T, Megna M
Clinical, Cosmetic and Investigational Dermatology 2024, 17:829-842
Published Date: 10 April 2024
The Past, the Present and the Future of Teledermatology: A Narrative Review
Tommasino N, Megna M, Cacciapuoti S, Villani A, Martora F, Ruggiero A, Genco L, Potestio L
Clinical, Cosmetic and Investigational Dermatology 2024, 17:717-723
Published Date: 21 March 2024
Long-Term Efficacy of Guselkumab in an Adolescent Hidradenitis Suppurativa Patients: A Case Report
Martora F, Battista T, Potestio L, Portarapillo A, Tommasino N, Megna M
Clinical, Cosmetic and Investigational Dermatology 2024, 17:483-487
Published Date: 29 February 2024
L-Lysine as an Alternative Treatment for Pityriasis Rosea (PR) [Response to Letter]
Potestio L, Martora F, Cacciapuoti S, Megna M, Villani A, Ruggiero A
Clinical, Cosmetic and Investigational Dermatology 2024, 17:463-464
Published Date: 24 February 2024
Secukinumab in Hidradenitis Suppurativa Patients Who Failed Adalimumab: A 52-Week Real-Life Study
Martora F, Marasca C, Cacciapuoti S, Fariello F, Potestio L, Battista T, Scalvenzi M, Megna M
Clinical, Cosmetic and Investigational Dermatology 2024, 17:159-166
Published Date: 23 January 2024
Pityriasis Rosea and Pityriasis Rosea-Like Eruption Following COVID-19 Vaccination: A Narrative Review
Potestio L, Martora F, Cacciapuoti S, Megna M, Villani A, Ruggiero A
Clinical, Cosmetic and Investigational Dermatology 2024, 17:51-57
Published Date: 8 January 2024
A Case of Erythrodermic Psoriasis Successfully Treated with Risankizumab
Megna M, Ruggiero A, Salsano A, Lauletta G, Portarapillo A, Torta G, Martora F, Potestio L
Clinical, Cosmetic and Investigational Dermatology 2023, 16:3503-3507
Published Date: 5 December 2023
Herpes Zoster and COVID-19 Vaccination: A Narrative Review
Potestio L, Megna M, Villani A, Cacciapuoti S, Scalvenzi M, Martora F
Clinical, Cosmetic and Investigational Dermatology 2023, 16:3323-3331
Published Date: 16 November 2023
JAK Inhibitors in Psoriatic Disease
Megna M, Potestio L, Ruggiero A, Cacciapuoti S, Maione F, Tasso M, Caso F, Costa L
Clinical, Cosmetic and Investigational Dermatology 2023, 16:3129-3145
Published Date: 31 October 2023
Effectiveness of Brodalumab in Patients with Moderate-to-Severe Plaque Psoriasis Located in Difficult-to-Treat Areas
Cacciapuoti S, Potestio L, Guerrasio G, Fabbrocini G, Scalvenzi M, Ruggiero A, Caiazzo G, Megna M
Clinical, Cosmetic and Investigational Dermatology 2023, 16:2637-2644
Published Date: 25 September 2023
Guselkumab, Risankizumab, and Tildrakizumab in the Management of Hidradenitis Suppurativa: A Review of Existing Trials and Real-Life Data
Martora F, Scalvenzi M, Battista T, Fornaro L, Potestio L, Ruggiero A, Megna M
Clinical, Cosmetic and Investigational Dermatology 2023, 16:2525-2536
Published Date: 18 September 2023
Biologics for the Management of Erythrodermic Psoriasis: An Updated Review
Potestio L, Camela E, Cacciapuoti S, Fornaro L, Ruggiero A, Martora F, Battista T, Megna M
Clinical, Cosmetic and Investigational Dermatology 2023, 16:2045-2059
Published Date: 4 August 2023
Nail Psoriasis: An Updated Review of Currently Available Systemic Treatments
Battista T, Scalvenzi M, Martora F, Potestio L, Megna M
Clinical, Cosmetic and Investigational Dermatology 2023, 16:1899-1932
Published Date: 24 July 2023
Use of Biological Therapies for the Management of Pustular Psoriasis: A New Era?
Megna M, Camela E, Ruggiero A, Battista T, Martora F, Cacciapuoti S, Potestio L
Clinical, Cosmetic and Investigational Dermatology 2023, 16:1677-1690
Published Date: 28 June 2023
Effectiveness and Safety of Deucravacitinib for the Management of Psoriasis: A Review of the Current Literature
Potestio L, Ruggiero A, Fabbrocini G, Martora F, Megna M
Psoriasis: Targets and Therapy 2023, 13:19-26
Published Date: 4 May 2023
Safety and Efficacy of Covid-19 Vaccination in Patients Undergoing Biological Treatments for Psoriasis
Potestio L, Martora F, Fabbrocini G, Battista T, Megna M
Psoriasis: Targets and Therapy 2023, 13:11-18
Published Date: 12 April 2023
Tildrakizumab for the Treatment of Moderate-to-Severe Psoriasis: Results from 52 Weeks Real-Life Retrospective Study
Ruggiero A, Fabbrocicni G, Cacciapuoti S, Potestio L, Gallo L, Megna M
Clinical, Cosmetic and Investigational Dermatology 2023, 16:529-536
Published Date: 27 February 2023
Efficacy and Safety of Tildrakizumab in a Patient with Chronic HBV Infection
Potestio L, Piscitelli I, Fabbrocini G, Martora F, Ruggiero A, Megna M
Clinical, Cosmetic and Investigational Dermatology 2023, 16:369-373
Published Date: 5 February 2023
Adalimumab, Ustekinumab, and Secukinumab in the Management of Hidradenitis Suppurativa: A Review of the Real-Life Experience
Martora F, Megna M, Battista T, Potestio L, Annunziata MC, Marasca C, Villani A, Fabbrocini G
Clinical, Cosmetic and Investigational Dermatology 2023, 16:135-148
Published Date: 19 January 2023
The Role of Teledermatology During the COVID-19 Pandemic: A Narrative Review
Ruggiero A, Martora F, Fabbrocini G, Villani A, Marasca C, Megna M, Fornaro L, Comune R, Potestio L
Clinical, Cosmetic and Investigational Dermatology 2022, 15:2785-2793
Published Date: 19 December 2022
Cutaneous Reactions Following COVID-19 Vaccination: A Review of the Current Literature
Martora F, Battista T, Marasca C, Genco L, Fabbrocini G, Potestio L
Clinical, Cosmetic and Investigational Dermatology 2022, 15:2369-2382
Published Date: 6 November 2022
Towards Personalized Medicine in Psoriasis: Current Progress
Camela E, Potestio L, Ruggiero A, Ocampo-Garza SS, Fabbrocini G, Megna M
Psoriasis: Targets and Therapy 2022, 12:231-250
Published Date: 1 September 2022
Long-Term Efficacy and Safety of Guselkumab for Moderate to Severe Psoriasis: A 3-Year Real-Life Retrospective Study
Megna M, Potestio L, Fabbrocini G, Ruggiero A
Psoriasis: Targets and Therapy 2022, 12:205-212
Published Date: 14 July 2022
Efficacy and Safety of Anti-TNF Biosimilars for Psoriasis in Pediatric and Geriatric Populations: A 72-Week Real-Life Study
Megna M, Fornaro L, Potestio L, Luciano MA, Nocerino M, Delfino M, Guarino M, Fabbrocini G, Camela E
Psoriasis: Targets and Therapy 2022, 12:199-204
Published Date: 9 July 2022
Bimekizumab for the Treatment of Psoriasis: A Review of the Current Knowledge
Ruggiero A, Potestio L, Camela E, Fabbrocini G, Megna M
Psoriasis: Targets and Therapy 2022, 12:127-137
Published Date: 8 June 2022